The domestic pharmaceutical market grew at 12 per cent y-o-y in February, broadly in line with the average of 12.9 per cent since April 2015, primarily due to steady volumes, sustained healthy price hikes and new launches, a report said. “The Indian Pharmaceutical Market (IPM) reported moderate revenue growth of 12 per cent y-o-y in February 2016 as against 18.9 per cent in February 2015, primarily attributable to steady volumes, sustained healthy price hikes and new launches,” a report by Religare Institutional Research said here.
Therapy-wise, the anti-diabetic, cardiac, derma and gastrointestinal segments outperformed IPM growth by 4-6 per cent. The respiratory and anti-infective segments were laggards, it said. According to pharmaceutical market research company AIOCD AWACS, volumes, prices and new launches contributed 3.7 per cent, 5.4 per cent and 3 per cent respectively to domestic market growth.